Aura Sleep · Breakthrough Brief

Executive Summary

Flat topline, climbing CAC, illegible differentiation — and 70% of spend trapped in two channels.

Three years of 38% compounding stopped in one year. Spend didn't fall; what it bought did. The diagnosis is not a demand problem — it's three structural faults that only became visible when acquisition stopped being cheap enough to paper over them.

$0M

Trailing-12-mo revenue · flat YoY

+0%

CAC inflation · $79 → $112 (Google +58%)

Blended ROAS · down from 2.6x

Spend in Google + Meta · concentration risk

Working — real, durable assets

A genuine product moat — phase-change cooling fabric at 58% gross margin
A loyal, vocal base — 4.6★ across 6,800 reviews, unusually emotional for bedding
An authentic founder origin — the fabric built for his wife during the change
A high-intent cohort self-identifying — ~17.5% of on-site search is hormonal
Healthy unit economics underneath the noise — $240 AOV · 58% margin

Broken — and all three are fixable

Wrong target — creative is built for a persona 7 years younger than the median buyer
Wrong ruler — 7-day last-click defunds every asset that builds demand
Two auctions — 70% of spend in the two channels whose CPMs rose fastest
Illegible differentiation — "cooling" is a claim every competitor now makes
Under-monetized adjacency — sleepwear at 8% of revenue, mis-positioned

The takeaway: the product converts and the market is growing. Four moves get to a credible ~30% growth path (~$45M) through positioning, not more spend: Prove it (make brand spend legible) → Own it (reposition around The Change) → Fuel it (reactivate proven creative, capture existing intent) → Broaden & expand (off-platform demand the category can't follow).

Before the Plan · The Plan You Were Taking to the Board

"Scale Google 40% and grow into the number."

It is the answer the current measurement gives, and it is the answer we would give too if the 7-day window were telling the truth. It isn't. Here is what each plan costs and what each one buys — modeled on the same demand curve, the same margin, and the same twelve months.

"It feels like the obvious answer, and the obvious answer hasn't been working. I keep buying more of my best-measured channel and the topline doesn't move. Either the measurement's lying to me or I'm missing something upstream of the click." Maya Chen · CMO · kickoff call, 28 May 2026

	Plan A · Scale Google +40%	Plan B · This Brief
Total marketing spend	$9.7M (+15%)	$8.4M (flat)
Google spend	$3.2M → $4.5M	$3.2M → $2.2M
What the incremental dollar buys	Head-term auction depth	Unclaimed intent + off-platform reach
Modeled Google CAC at that volume	$95 → ~$118	$95 → ~$88
Modeled blended CAC · 12 mo	~$126	≤$90
Modeled blended ROAS · 12 mo	~1.6x	2.3x+
Modeled revenue · 12 mo	~$37.5M (+7%)	~$45M (~30%)
Channel concentration at exit	78% in two auctions	56% in two auctions
What you learn either way	Whether Google can absorb more	What your brand spend is actually worth

The structural problem with Plan A: Google is not a demand source, it is a demand harvester. Buying 40% more harvest capacity against a demand pool that isn't growing bids you against yourself — which is most of the +58% Google CAC story already on the books. Plan A's most likely outcome isn't failure, it's an expensive repeat of the year you just had: more spend, marginal growth, and no new information.

Performance & Attribution

The 7-day ruler over-credits Google and starves everything that builds the brand.

Last-click on a 7-day window is the measurement standard here. It systematically over-credits intent capture and under-counts the demand-creation channels that make someone search Aura in the first place. Incremental ROAS runs above last-click — the window is defunding the moat. [attribution-window-distortion]

Channel	Last-click credit	First-touch share	Credit gap	Read
Google	51%	24%	+27 pts	Over-credited
Meta	28%	29%	−1 pt	Undervalued at the margin
TikTok	4%	14%	−10 pts	Most undervalued
Affiliate / PR	9%	17%	−8 pts	Undervalued
Email / SMS	8%	4%	+4 pts	Over-credited (retention, not acquisition)
Other · CTV, podcast	<1%	12%	−11 pts	Effectively invisible

Read the last two rows together: the 4% of budget in "other" is producing 12% of first touches and receiving under 1% of credit. The ruler is not merely imprecise — it is systematically biased against every channel that creates demand, and the budget follows the credit.

The Creative Library Audit · 12 assets with meaningful spend

Ranked by 7-day CPA, the library is upside down.

We pulled every asset with over $40K behind it and scored each on two axes: the 7-day CPA the budget decisions were made on, and a brand-lift index built from aided-recall lift and branded-search response per $1K of delivery. The two rank orders are almost perfectly inverted — correlation −0.71.

Asset	Format	Spend	7-day CPA	Brand-lift index	Budget verdict
BSL 144	Retargeting · dynamic product	$390K	$61	12	Scaled
BSL 104	Product-on-white hero · sheet set	$612K	$86	31	Scaled
BSL 107	Thermal heat-map visualization	$548K	$91	38	Scaled
BSL 124	Price comparison · "$80 vs $200"	$141K	$102	29	Held
BSL 121	Lifestyle couple · morning	$233K	$118	44	Throttled
BSL 112	"Engineered sleep" brand film · 30s	$180K	$147	66	Throttled
BSL 136	Thermostat-war couples · 15s	$67K	$149	77	Retired
BSL 133	Review-quote static · "first real sleep"	$44K	$155	62	Cut
BSL 119	Clinical-MD thermoregulation explainer	$94K	$163	71	Cut
BSL 128	Founder origin · "he built it for his wife"	$76K	$171	84	Retired
BSL 131	UGC night-sweat testimonial	$58K	$184	89	Cut
BSL 141	Sleepwear launch · lifestyle	$210K	$206	22	Still running

Brand-lift index: 0–100 composite of aided-recall lift and branded-search response per $1K delivered, normalized across the library. Spend figures are trailing 12 months.

The three assets with the highest brand lift in the entire library — the founder origin, the clinical explainer, and the night-sweat testimonial — are the three that got cut. The lowest-brand-lift asset in the library is the one taking the largest budget. And BSL 141, the sleepwear launch, is the only asset failing on both axes and the only one still running unexamined. The ruler couldn't see what was working. Fixing the ruler is the keystone that unlocks every other move.

Key Research Insight

A large, growing category — with a cohort whose need is acute and unmet.

$0B+

US bedding ex-mattress [bedding-market-sizing]

Top of category growth band (6.5–8.8%/yr)

Peri women sleeping <7h vs 32.5% before

Two draped fabrics side by side — textured dusty blue and smooth cream satin folded into a deep swirl with warm golden light glowing from within

The whitespace competitors can't take. Cooling is a red-ocean arms race — Eight Sleep alone raised $100M (Aug 2025) + $50M at a $1.5B valuation [competitor-moves-2025-2026]. "Cooling" is now a feature everyone claims. But none of them can own peri/menopause without abandoning the positioning they've already built. The change is open ground.

The Competitive Map · Why This Position Is Structurally Defensible

Everyone says cooling. Nobody can say this.

The test isn't whether a competitor could run a menopause ad. It's whether they could run it without contradicting the brand they've spent years and hundreds of millions building. For the two that matter most, the answer is no.

Competitor	Position they've bought	Est. annual media	Why they can't follow you here
Eight Sleep	Performance tech · optimization · the quantified athlete	$60–80M	Their entire equity is upgrade, not relief. A menopause campaign reads as a downgrade to a brand selling peak performance to 32-year-old founders — and their hardware price point excludes most of the cohort.
Brooklinen	Mid-premium taste · "nice sheets" default	$45–60M	Their advantage is breadth and neutrality. Naming a life stage narrows the aperture on a brand whose whole proposition is that it's for everyone. They'll add a cooling SKU; they won't take a position.
Cozy Earth	Luxury cooling · celebrity endorsement	$25–40M	Closest threat on the claim, furthest on the credibility. Bamboo viscose is a comfort story, not a materials-science one — they cannot make the thermal argument hold under scrutiny.
Saatva	Luxury bedding & mattress · showroom trust	$70–90M	Mattress-led economics. Bedding is an attachment sale, not a category they'll fight a positioning war over.
Slumber Cloud	Functional cooling · NASA-derived PCM	$5–10M	The one genuine materials peer — and the one currently ranking on "best sheets for night sweats." Under-capitalized. Speed matters here.
Bedgear	Performance sleep · retail-led	$8–15M	Wholesale-first, athletic positioning, negligible DTC brand-building.
Amazon-native tail	$80–120 "cooling" search arbitrage	Ad-spend only	They compete on the word, not the product. They muddy the claim for everyone — which is exactly why a claim they can't imitate is worth more than a claim they can.

The brands actually talking to her

Midi Health, Evernow, Bonafide — midlife women's health, and they've solved the tone: relief, not shame
They have the trust and the audience — and no physical product for the 3am problem
None of them are bedding competitors. All of them are potential partners — this is the Prescribe the Proof bet
Aura is currently absent from this conversation entirely, despite selling into it by accident

What the tail is doing to your claim

The word "cooling" now costs $6.80 CPC and returns an undifferentiated results page
The stated objection is already price-anchored: "how is this different from the $80 version"
Every dollar spent defending the generic claim is spent in the auction they've inflated
A named use case moves the argument off price and onto fit — where the tail can't compete

The Evidence · Four Independent Sources, One Customer

This cohort was not selected. It was discovered.

A reposition asks the board to bet the lead narrative. That bet is only defensible if the customer arrives from the data rather than from a strategy offsite. Four datasets that don't talk to each other point at the same person.

01 · Who checks out

68% female · median age 47

Against a stated persona of 35–55. The concentration is 40–58, seven years older at the median than the creative is built for.

02 · What they search on-site

~17.5% hormonal queries

72,100 of 412,000 annual on-site searches are hormonal or life-stage — a cluster nobody designed a single page for.

03 · What they say post-purchase

22% cite hormonal temperature

Of female buyers, in an open-text "why did you buy" field where the word "menopause" was never prompted.

04 · What they write in reviews

890 unprompted mentions

Menopause or perimenopause named without prompting across the 6,800-review corpus — 13% of all reviews.

Source 02 · On-site search · the queries nobody built a page for

Query	Annual searches	Results returned	Search→purchase CVR	What happens today
night sweats	18,400	3 (generic)	4.4%	Returns the standard sheet set. No mention of the use case.
hot flashes	15,900	0	1.1%	Empty results page. She leaves.
menopause sheets	11,200	0	0.9%	Empty results page. She leaves.
perimenopause	8,600	0	1.3%	Empty results page.
hormonal sleep	5,300	0	1.6%	Empty results page.
menopause night sweats bedding	4,700	2	5.1%	Highest-converting query on the site. Zero supporting content.
hot flash pajamas	4,100	1	6.2%	Routes to the sleepwear line — the line that "underperformed projections." It was never mis-built. It was mis-positioned.
cooling pajamas menopause	1,600	1	5.8%	Same page. Same signal.
tamoxifen night sweats	2,300	0	—	Survivors on endocrine therapy, arriving on their own. This is where the Tamoxifen bet came from.

Read the CVR column, not the volume column. Site-average search→purchase conversion is 2.6%. Every hormonal query that returns a relevant result converts at 4.4–6.2% — up to 2.4× site average. Every hormonal query that returns nothing converts at ~1%. The cohort is the highest-intent traffic on the site and roughly 41,000 of them a year hit an empty page.

Source 04 · The 6,800-review corpus, clustered

Read the bottom two rows. 610 reviews describing a thermostat argument is the entire Thermostat Treaty, already written by customers. And 96 reviews naming cancer treatment — 1.4%, easy to dismiss as noise — is a cohort for whom HRT is contraindicated and cooling is one of the few available levers. Small numbers with acute need are how category-defining positions start.

What the four sources build

72,100 hormonal searches

Highest-intent traffic on the site

↘

6,800 reviews · 4.6★

1,240 name night sweats unprompted

→

The Change Platform

"Engineered for the change" — relief, not shame

The founder's origin

He built it for his wife, during the change

↗

↓

Three revenue lines

Core cohort · repositioned sleepwear · couples

The Segment Map

Win the core first. Broaden deliberately. Let the halo pull.

Core

Own it — where we win first

"The Change" — women 40–58

The peri/menopause sleep sufferers the buyer data already shows converting. Lead narrative and hero creative are built here.

Est. reachable: 11–14M US women · CAC target: ≤$90 · Share of plan: ~60% of working media

Expand

Broaden — adjacent demand

Thermostat-conflict couples & hot sleepers

19% report partner temperature conflict; 41% run hot. The breadth ladder under the Change platform.

Est. reachable: 20M+ households · CAC target: ≤$105 · Share of plan: ~25%

Halo

Aspire — pull, don't push

Wellness-optimizing affluent

Premium sleep optimizers who lift brand prestige. Served by halo, not dedicated spend.

Est. reachable: 8M · CAC target: unmanaged · Share of plan: ~15%, brand only

Note what changed and what didn't. The halo segment is the persona the brand has been buying against for three years — it stays in the plan, at 15%, served by brand halo rather than dedicated performance spend. This is a reallocation of emphasis, not an abandonment. That distinction is the answer to the pigeonhole objection.

Portfolio on a Page

Sequenced by confidence, not by hope.

Horizon	Move	North-star	Read	Confidence
Prove · now	The Holdout Board Deck — the enabler, sequenced first	iROAS vs last-click	4–6 wk	High
Own · 0–30d	The Change Platform — the keystone reposition	Cohort CAC ≤$90	4–8 wk	High
Fuel · 0–30d	Reinstate The Two — BSL 128 + BSL 119 under holdout	iROAS on reinstated assets	4 wk	High
Fuel · 0–30d	2AM Truths Engine — 10 review-mined story units	Hold rate vs library median	3 wk	High
Fuel · 0–30d	Night-Sweat Search Capture — 5 LPs + SEM cluster	Hormonal-LP CVR >4%	2–4 wk	High
Broaden · 30–60d	Thermostat Treaty — the breadth ladder	Couples-cohort CAC	3–6 wk	Mid
Frontier · 60–90d+	The Insomnia Daypart — 1–4am CTV / audio	Next-morning branded search	6–8 wk	Mid
Frontier · 60–90d+	Prescribe the Proof — menopause telehealth	≥1 pilot LOI	90 d	Low
Frontier · 60–90d+	The Tamoxifen Cohort — survivors on endocrine therapy	≥1 community partnership	90 d	Low

Five High-confidence moves (fast, proven, ≤4-week read), two Mid, and two Low — the asymmetric bets where the metric is a signed pilot or partnership, not 90-day revenue. The Holdout raises the confidence of half the portfolio once it reads, which is why it is sequenced first even though it produces no revenue itself.

Prove it · the keystone enabler

Prove the brand pays — the Holdout Board Deck.

Side-by-side comparison of two minimalist bedroom setups with linen bedding, each with a light wood side table and olive tree

Run a geo/matched-market holdout on reinstated brand creative to prove incremental ROAS to a last-click-anchored board. Make brand spend legible — the keystone that unlocks budget for every other play.

Converts the measurement argument into board-grade evidence at 90% CI
A proven, board-defensible method — not "trust us, it's brand"
Raises the confidence of half the portfolio once it reads

The design · pre-registered before a dollar moves

24 matched DMAs — 12 test, 12 control, paired on trailing-90-day revenue per capita, seasonality profile and baseline branded-search volume
Brand creative dark in control — BSL 128, 119, 136 and the 2AM Truths units run in test markets only; search and retargeting run unchanged in both, so the only variable is demand creation
$340K incremental over 6 weeks — 4.9% of a quarter's spend, ring-fenced and pre-approved
MDE 12% lift on branded search at 90% CI, power 0.8 — the DMA count is sized backward from this number, not chosen for convenience
Two reads: branded-search lift at week 2 as the early signal, incremental ROAS at week 6 as the decision
Pre-registered analysis plan — the success threshold is written down and circulated before the test starts, so the result can't be re-litigated after the fact

North-star: iROAS gap vs 7-day last-click (geo-matched holdout). Backup: if the board resists the methodology, fall back to brand-search-lift as the proof metric — design to read first-touch early, not just conversions.

The asymmetry: the cost of running this and being wrong is $340K. The cost of not running it is that every brand dollar for the next three years keeps getting adjudicated by a ruler we already know is biased — and the assets with the highest brand lift in the library keep losing the budget fight to a retargeting ad.

Own it · keystone positioning

The Change Platform — own the customer the data already shows is buying.

A woman in slate-grey loungewear sits on the edge of a bed looking out a large window at a soft dawn sky, surrounded by dusty blue and teal linens

Reposition the lead narrative around "engineered for the change" — a life-stage sleep platform owning peri/menopause temperature relief, without clinical or shame framing. Relief, not shame.

Buyer data already validates the cohort — ~17.5% of on-site search is hormonal
Owning the named use case expands the addressable market, not narrows it
De-risked against the founder's pigeonhole fear by the Thermostat Treaty breadth ladder

The message hierarchy · what leads, what supports, what closes

Lead — recognition. The 3am moment, in her words. No product for the first 5 seconds. "That's me" before "that's a sheet."
Support — mechanism. Phase-change material, engineered by a materials scientist. The proof that this isn't the $80 version, delivered as reassurance rather than as headline.
Support — origin. He built it for his wife. The single most credible sentence the brand owns, and it has been sitting on the About page for a year.
Close — relief. Not "manage your symptoms." Sleep through the night.

The lexicon · relief, not shame

Say this	Never this
Engineered for the change	A menopause product
Night sweats	The change of life
Sleep through the night	Symptom management
Your temperature, regulated	Anti-aging · turn back the clock
She was up four times a night	Suffering from menopause
Designed with a clinical sleep advisor	Doctor recommended · clinically proven
Relief	Treatment · therapy · remedy

Regulatory guardrail: Aura sells a comfort textile, not a medical device. No copy may claim to treat, prevent or reduce hot flashes, night sweats or any hormonal symptom — testimonials describing personal sleep experience are permitted, efficacy claims are not. The clinical sleep advisor may be credited as a design collaborator; she may not be used to imply medical endorsement. All Change Platform copy routes through a single-pass regulatory review before it ships.

North-star: "The Change" cohort CAC vs blended $112; life-stage LP CVR above site average within 4 weeks. Guard against "menopause product" shame-avoidance with the relief-not-shame lexicon — and A/B the explicit framing against the implicit "3am" framing in the first two weeks, so the tone question is answered with data rather than opinion.

Fuel it · quick wins & the creative engine

Two fast Tier-1 proof points while the Holdout runs.

Reinstate The Two High

Bring back the two highest brand-lift creatives that were cut — founder story (BSL 128) and clinical-MD (BSL 119) — and run them under a 30-day holdout so they earn budget on incremental contribution, not 7-day CPA. Live within 1 week; no production cost, the assets exist.

Night-Sweat Search Capture High

Dedicated LPs + search against hormonal/life-stage queries — already ~17.5% of on-site search. High-intent, low-cost, fast demand capture. Pages live in 2 weeks; measure CPA on hormonal-query LPs vs generic "cooling" LPs.

The 2AM Truths Engine

Industrialize the 6,800-review corpus into a creative factory.

Close-up of a hand with a wedding band resting on dark grey-blue bedsheets in a dimly lit bedroom, warm bedside lamp glow

Turn the reviews into a continuous factory of UGC-style night-sweat testimonial units — scaling the exact format (BSL 131) that was killed for failing 7-day CPA. Real voice-of-customer beats polished ads for this audience. Depends on the Holdout lens for budget defense; without it, units get re-cut under 7-day last-click.

The story bank · ten units, mined from the corpus, ranked by cluster size

These are not concepts written in a room. Each one is the dominant phrasing of a review cluster — the hook line is close to verbatim, and the cluster size is the number of reviews expressing that specific experience.

#	Story	Hook line	Cluster	Segment
1	The Second Pajamas	"I kept a spare set on the floor next to the bed. That was just my life."	410	Core
2	The Towel on the Sheet	"I slept on a bath towel for two years so I wouldn't soak the mattress."	280	Core
3	The Freezer Pillow	"I kept my pillowcase in the freezer. I'm 49 years old."	190	Core
4	First Real Sleep in Years	"I cried the first morning I woke up and hadn't moved all night."	340	Core
5	The Doctor Shrug	"My doctor said it's just part of it. Nobody mentioned the bed."	220	Core
6	The Thermostat Treaty	"We were two degrees away from a real problem."	610	Expand
7	The Guest Room	"I moved into the guest room. I told him it was my snoring."	160	Expand
8	He Built It For Her	The origin, retold in the founder's voice — the BSL 128 revival, produced properly this time.	—	All
9	The Tamoxifen Year	"Five years on tamoxifen. HRT isn't an option for me. This was."	96	Frontier
10	The Hotel Test	"I pack my own sheets for vacation. My husband thinks I'm insane. I sleep."	130	Halo

Production plan

10 units · vertical 9:16 · 30–60s · shot to read as real, not as a brand film
Cast from the review corpus — reach out to consenting reviewers first; supplement via UGC marketplaces only where needed
$18–25K total ($1.8–2.5K per unit) — under 0.3% of annual media
Cadence: 10 in the first 3 weeks, then 4–6 per month as an always-on engine
Distribution: Meta + TikTok in test DMAs under the holdout; the winners graduate to the Insomnia Daypart

Guardrails on the format

Consent and compensation in writing for every reviewer whose words are used, even paraphrased
No efficacy claims — personal experience only; a reviewer may say she slept, she may not say the product treated anything
No age-shaming, no before/after bodies — the failure mode of this category is making her feel like the problem
Unit 9 does not ship until the oncology-community review in the Tamoxifen bet has signed off on tone
Retire below 30% completion after 2 weeks of delivery

Night-Sweat Search Capture · Paid + Organic

The demand already exists. It costs a third of what you're paying now.

The head term "cooling sheets" is the most expensive real estate in the category and returns a page where Aura is indistinguishable from an $80 Amazon listing. The hormonal cluster is cheaper, higher-intent, and in most cases unclaimed by any bedding brand at all.

Confidence90%

The highest-confidence move in the sprint. This is not a bet on whether the demand exists — the on-site logs already prove it does and prove it converts. The only work is building pages for it.

Query cluster	Est. US vol/mo	Avg CPC	Aura position	Who holds it today
cooling sheets (the head term)	74,000	$6.80	p1 paid, p9 organic	Everyone. The red ocean — and 38% of Google budget.
perimenopause sleep help	22,200	$1.60	Not ranked	Midi, Evernow — health brands, no product for the bed
menopause night sweats sheets	12,100	$2.40	Not ranked	Nobody. Open ground.
cooling sheets for hot flashes	9,900	$3.10	p3 organic, no paid	Cozy Earth
best sheets for night sweats	8,100	$2.85	Not ranked	Slumber Cloud — the one real materials peer, under-capitalized
hot flash pajamas / cooling sleepwear menopause	6,600	$2.05	Not ranked	Nobody. And Aura already sells the product.
hot flash bedding	5,400	$2.20	Not ranked	Nobody
tamoxifen night sweats relief	3,600	$1.90	Not ranked	Nobody — and the searcher is in a five-year window of acute need
night sweats but not menopause	4,400	$1.45	Not ranked	Nobody — the diagnostic-anxiety entry point into the cohort

The arithmetic: the hormonal cluster totals ~72,300 monthly searches at a blended $2.24 CPC against the head term's $6.80 — 67% cheaper traffic, higher measured on-site conversion, and in five of nine clusters no bedding competitor is bidding at all. This is not a growth hack; it is the same demand Aura already converts, bought at a third of the price, from a page that finally acknowledges what she typed.

Five Landing Pages · one template, five arguments

Stop sending hormonal queries to a generic PDP.

Each page is a variation on one template — same components, different content modules — so the build is two weeks of work, not a site redesign. Every page carries its own conversion event so cohort CAC is measurable from day one.

Element	Homepage	/the-change	/night-sweats	/thermostat	/sleepwear
Hero headline	Engineered for the change	You're not imagining the 3am	The bed that doesn't hold your heat	Two degrees from a real argument	Sleepwear that doesn't hold the sweat
Lead proof	Founder origin · 30s	Founder origin + 2 story units	Thermal mechanism · heat-map	Couples testimonial (BSL 136)	Fabric + the "hot flash pajamas" query answered
Hero product	Sheet set	Sheet set + pillow bundle	Sheet set	Dual-zone bundle	Sleepwear + pillowcase
Objection handled	"Isn't this just expensive sheets?"	"Is this a menopause brand?"	"How is this different from the $80 one?"	"Will it work for both of us?"	"Why not just cotton?"
Social proof module	4.6★ · 6,800 reviews	Reviews filtered to the cohort	Reviews filtered to night sweats	Reviews filtered to couples	Reviews filtered to sleepwear
Mechanism depth	Short	Medium · advisor-credited	Full · phase-change explainer	Short	Medium
Primary CTA	Shop the bed	Start with the sheets	Start with the sheets	Build your dual-zone bed	Shop sleepwear
Feeds which move	Brand halo	Change Platform	Search capture	Thermostat Treaty	Search capture · line rescue

The sleepwear finding pays for the whole build. A line at 8% of revenue that "underperformed projections" turns out to be the answer to 6,600 monthly searches nobody is bidding on and the highest-converting query on the site (6.2%). It was never a product failure — it was a page that never said the words she typed. Repositioning it is a two-week copy change against an inventory position you already own.

Broaden it · the breadth ladder

Thermostat Treaty — so the menopause-lead bet never reads as audience-narrowing.

Top-down view of a bed split vertically into cool tones on the left and warm tones on the right, a mustard throw draped across the corner

Reactivate the high-brand-lift "thermostat war" couples creative as an expansion campaign, plus a dual-zone bundle — targeting the 19% with partner conflict and the 41% who run hot.

Deliberately broadens demand and de-risks the founder's pigeonhole fear
Reinstates already-proven couples creative (BSL 136, brand-lift index 77)
A dual-zone bundle creates a new attach story — and the first genuine reason for a second purchase in a durable category
610 reviews already describe the thermostat argument unprompted — the campaign is transcription, not invention

Why this is the answer to the pigeonhole objection

It ships inside the same 60 days as the Change Platform, not after it — so there is never a quarter where the brand looks like a single-cohort brand
It sits under the Change Platform architecturally: same fabric story, same "your temperature, regulated" line, wider door
It converts the core insight into a household purchase — one buyer, two sleepers, a bigger basket
It gives the halo segment a way in that doesn't require them to identify with the core cohort at all

Architect it under the Change Platform so it doesn't split focus or budget; watch bundle gross-margin dilution — price the dual-zone as an upgrade, never as a discount. North-star: couples-cohort CAC below blended, and attach rate on the dual-zone bundle above 12%.

Three asymmetric bets

Channels the cooling clones can't copy.

Folded bedding fabric with a gradient from deep teal-blue through a thin golden stripe to warm beige on dark stone — Prescribe the Proof · telehealth

A dimly lit bedroom at night with a warm bedside lamp and an open window revealing distant city lights — The Insomnia Daypart · 1–4am

A tranquil bedroom in soft natural light, a rustic nightstand with an open book and ceramic mug, green trees through the window — The Tamoxifen Cohort · survivors

Bet	Why it's uncopyable	North-star	Confidence
Prescribe the Proof Menopause telehealth (Midi, Evernow, Maven)	Borrows the "relief not shame" equity of brands customers already trust; a channel Brooklinen / Eight Sleep / Cozy Earth structurally cannot follow	≥1 pilot LOI in 90d	Low
The Insomnia Daypart 1–4am CTV / audio / podcast	Reach her while she's literally awake in bed — near-zero competition for the daypart; reuses existing 2AM Truths creative, off Google/Meta/TikTok/IG	Next-morning branded search vs holdout	Mid
The Tamoxifen Cohort Survivors on endocrine therapy	Drenching night sweats are the #1 QoL complaint and HRT is contraindicated — cooling bedding is one of the only levers; a non-discretionary, high-loyalty cohort no Amazon clone can serve	≥1 oncology-community partnership	Low

How each one actually gets run

Bet	Budget · 90d	First 30 days	Days 30–90	Kill condition
Prescribe the Proof	$40K (BD, not media)	Map the 9 largest menopause telehealth and midlife-clinic networks; warm intros through the clinical sleep advisor; build the member-benefit pitch (discount + education, not a referral fee)	Two pilots scoped; one signed LOI; co-branded education asset in market with a single partner	No LOI at 90 days → park the bet, keep the relationships, do not fund media
The Insomnia Daypart	$120K	Buy 1–4am CTV and streaming-audio inventory in the 12 holdout test DMAs only; run 3 of the 2AM Truths units unmodified — no daypart-specific production	Read next-morning branded search against control DMAs; if positive, extend to podcast and expand the daypart to 11pm–4am	No measurable next-morning branded-search lift after $120K / 6 weeks → kill
The Tamoxifen Cohort	$25K	Oncology-nurse review of all language; approach 3 survivor communities as a donor and listener before a seller; build a product-donation program	One community partnership formalized; unit 9 of the story bank ships only with community sign-off	Any signal the cohort experiences the outreach as predatory → stop immediately, no A/B test on this one

These are LTV/loyalty and partnership plays, not scale plays — patient, respectful cadences with no clinical claims. Total ring-fenced cost is $185K, or 2.2% of annual budget, and each is a 12-month-plan proof point that widens the moat where performance-ad velocity can't reach.

A note on the Tamoxifen bet. This cohort is reachable, underserved, and commercially attractive, which is exactly why it demands more restraint than the others. No health-condition targeting, no medical claims, no urgency mechanics, no discount-driven cadence. If it cannot be run in a way an oncology nurse would defend in public, it does not get run. The metric is a partnership, not a purchase.

The Model · Same $8.4M, Pointed Differently

Four quarters from $112 to ≤$90 — without a dollar of new budget.

Every move in this Brief is funded by reallocation, not by an increase. Scroll the trajectory — blended CAC falls as head-term spend rotates into unclaimed intent and off-platform reach, and the channel concentration unwinds along with it.

Modeled on the flat $8.4M budget

Today

$112 CAC · 1.8x ROAS

70% of spend in two auctions, 38% of it defending a head term where Aura is indistinguishable from an $80 listing. Off-platform is 4% of budget and produces 12% of first touches. This is the starting line.

Q1 · Prove

$108 CAC · holdout live

The Holdout runs in 24 matched DMAs. BSL 128 and 119 are back in market. The five landing pages ship and the hormonal search cluster switches on — cheap, high-intent traffic starts arriving at a page that answers it. Google spend edges down as generic head-term bids are trimmed.

Q2 · Own + Fuel

≤$100 CAC · reposition live

The Holdout has read. The Change Platform is the lead narrative, the 2AM Truths engine is shipping 4–6 units a month, and sleepwear has been repositioned against a query cluster nobody else is bidding on. Head-term spend rotates hard into the hormonal cluster at a third of the CPC.

Q3–Q4 · Broaden

≤$90 CAC · 2.3x ROAS

Thermostat Treaty widens the door and lifts basket size with the dual-zone bundle. The Insomnia Daypart and the first telehealth pilot carry off-platform to 18% of budget. Google and Meta fall to 56% of spend — the concentration risk is materially unwound.

The reallocation · annual, at a flat $8.4M

Channel	Today	Exit	Δ $	What changes
Google	38% · $3.19M	26% · $2.18M	−$1.01M	Exit generic head-term depth; keep brand defense and add the hormonal cluster at a third of the CPC
Meta	32% · $2.69M	30% · $2.52M	−$170K	Nearly flat dollars, entirely different creative — the story bank replaces product-on-white
TikTok	12% · $1.01M	13% · $1.09M	+$85K	The most under-credited channel on first touch gets a modest raise, now measurable under the holdout
Affiliate / PR	8% · $672K	7% · $588K	−$84K	Reweighted toward midlife-health publishers and away from generic deal affiliates
Email / SMS	6% · $504K	6% · $504K	—	Unchanged in dollars; segmented by cohort so retention creative matches acquisition creative
Off-platform · CTV, audio, telehealth, partnerships	4% · $336K	18% · $1.51M	+$1.18M	The Insomnia Daypart, the frontier bets, and the channels the category structurally can't follow
Google + Meta concentration	70%	56%	−14 pts	The concentration risk, materially unwound — on a flat budget

Incremental production and test costs — 10 story units ($18–25K), five landing pages ($30–40K), the Holdout's ring-fenced media ($340K) and the three frontier bets ($185K) — total roughly $600K, funded entirely out of the $1.01M rotated off Google head terms. Nothing here requires a budget increase; it requires permission to stop buying the most expensive traffic in the category.

Measurement & Confidence

Every move ladders to two board outcomes.

$112 → ≤$90

Blended CAC

1.8x → 2.3x+

Blended ROAS

The scorecard · what gets reported, and from where

Metric	Today	90 days	12 months	Source of truth
Blended CAC	$112	≤$100	≤$90	GA4 + Shopify reconciled, all spend ÷ all new customers
Blended ROAS	1.8x	2.0x	2.3x+	Same denominator; no platform-reported figures
"The Change" cohort CAC	not measured	≤$95	≤$80	Cohort-tagged LPs with dedicated conversion events
Incremental ROAS on brand	unknown	≥1.3x	≥1.5x	Geo holdout, 24 matched DMAs, 90% CI
Google + Meta share of spend	70%	64%	56%	Media plan of record
Hormonal-query sessions	72.1K/yr	+40%	~3×	GA4 site search + SEM query reports
Hormonal-LP conversion rate	n/a	>4.0%	>5.0%	GA4, per-page conversion event
Branded search volume index	100	112	135	Google Search Console, seasonally adjusted
12-month repeat rate	30%	31%	36%	Shopify cohort analysis
AOV	$240	$248	$265	Shopify — driven by the dual-zone bundle
Sleepwear share of revenue	8%	9%	14%	Shopify — the repositioned line

Kill & Scale Rules · hard rules, not guidelines

These exist to prevent the failure mode that produced the current situation: an underperformer running "a little longer," and a winner never getting the fuel because the ruler couldn't see it.

Kill rules · act immediately

Change-cohort CAC > $130 after $150K — the reposition is not the constraint; revert the lead narrative and re-diagnose
Hormonal-LP CVR < 2.0% after 1,500 sessions — rebuild the page; the message-to-page match is wrong, not the audience
Hormonal-cluster CPC > $4.50 sustained 2 weeks — the cluster is being bid up; shift weight to SEO and content
Insomnia Daypart: no next-morning branded-search lift after $120K / 6 weeks — kill the daypart, keep the creative
Telehealth: no signed LOI at 90 days — park it; keep the relationships, fund no media
Any story unit < 30% completion after 2 weeks of delivery — retire it
Tamoxifen cohort: any sign the outreach reads as predatory — stop, no test, no debate

Scale rules · pour fuel

Change-cohort CAC < $90 after $150K — double the cohort budget and build lookalikes off converters
Holdout iROAS ≥ 1.3x — reinstate the full brand slate and rotate head-term budget behind it, immediately
Hormonal-LP CVR > 4% — build the remaining pages plus a content hub against the cluster
Any story unit > 1.4× library median hold rate — cut 3 variants within a week and put it in the daypart
Dual-zone attach > 12% — make the bundle the default configuration on /thermostat
Sleepwear CVR holds > 5% on the repositioned page — expand the line rather than discount it

Measurement realism: distrust last-click — platform-reported CAC in this category typically runs well below true CAC. GA4 reconciled against Shopify is the source of truth; branded-search lift is the leading indicator; and blended CAC — all spend ÷ all new customers — is the only number that settles the board question. Each move also carries its North-Star KPI, guardrails, target, read window and confidence in the registry. Confidence mix: 5 High, 2 Mid, 2 Low.

Risk Register

What would have to go wrong — and what we've already done about it.

A reposition is the highest-variance move a brand can make. These are the seven ways this plan fails, ranked by expected cost, each with the mitigation already built into the sequencing rather than bolted on afterwards.

Risk	Likelihood	Impact	Mitigation — already in the plan
Shame-avoidance — the cohort rejects being named, and explicit framing depresses response	Medium	High	The relief-not-shame lexicon; explicit vs implicit "3am" framing goes to A/B in weeks 1–2, so tone is settled by data. The implicit framing is a designed fallback, not a retreat.
The board says no to the reposition	Medium	High	This is why the Holdout is sequenced first and costs $340K. The reposition ask arrives after the evidence, not instead of it.
Holdout reads inconclusive — underpowered or contaminated	Medium	High	24 DMAs sized backward from a 12% MDE at 90% CI; pre-registered analysis plan; branded-search lift as a designed backup metric that reads two weeks earlier.
Pigeonhole — the brand reads as menopause-only and the halo cools	Medium	Medium	Thermostat Treaty ships inside the same 60 days. The halo segment keeps 15% of plan. We reposition the lead narrative, never the house.
Competitive fast-follow — a funded competitor takes the position	Low–Med	Medium	Structurally unattractive to Eight Sleep and Brooklinen (see the competitive map). The real watch item is Slumber Cloud, who already rank — which is an argument for speed, not for hedging.
Regulatory / claims exposure — copy drifts into medical territory	Low	High	Single-pass regulatory review on all Change Platform copy; the lexicon table is binding, not advisory; the clinical advisor is credited as a designer, never as an endorser.
Tamoxifen cohort mishandled — reputational damage	Low	High	Oncology-nurse language review before anything ships; community partnership before commerce; no health-condition targeting; an unconditional stop rule with no A/B test attached.
Bundle margin dilution — dual-zone erodes the 58%	Low	Low	The bundle is priced as an upgrade, never as a discount; gross margin is a reported metric on the Thermostat Treaty scorecard, not an afterthought.

The risk of the alternative. Every risk above is bounded, sequenced and reversible. The risk in Plan A — scale Google 40% — is unbounded and invisible: it spends 15% more, learns nothing about what the brand is worth, and leaves the concentration problem larger than it found it. The safest-looking plan on the page is the one with no read at the end of it.

Roadmap & Timeline

Stand it up, launch, read, then scale into ~30% growth.

0–2 weeks · Stand it up

Design and pre-register the 24-DMA geo holdoutMOST · the enabler
Reinstate BSL 128 + BSL 119 in test marketsMaya · no production cost
Build the five landing pages off one templateWeb · 2 sprints
Launch the hormonal search cluster; trim generic head-term bidsMOST · paid search
Cluster the 6,800-review corpus; begin reviewer outreach and consentMOST · creative
Lexicon signed off; regulatory review path agreedMaya · clinical advisor

0–30 days · Launch

Change Platform creative and lexicon live as the lead narrativeMaya · keystone
Ship the first 10 story units; A/B explicit vs implicit framingMOST · 2AM Truths
Reposition and relaunch the sleepwear line against its query clusterMerch · line rescue
Stand up the Insomnia Daypart in the 12 test DMAsMOST · new frontier
Open telehealth BD; begin oncology-community listeningMaya · BD
Week-2 read: branded-search lift, early signalMOST · first checkpoint

Week 6 · The Holdout reads

iROAS vs 7-day last-click, 90% CI — the decision point for the whole portfolioMOST · Maya · board
If ≥1.3x: reinstate the full brand slate and rotate head-term budget behind itScale rule

30–60 days · Broaden

Thermostat Treaty live; dual-zone bundle in marketMerch · MOST
Kill/scale pass on every audience and page against the hard rulesMOST
Story-bank cadence to 4–6 new units per monthCreative engine

90 days · Tier-1 targets

CAC trending ≤$100; ROAS toward 2.0xBoard numbers
Validated Change cohort + a defensible attribution lensProven
≥2 reactivated high-BSL creatives; ≥1 off-platform pilot LOI or partnershipFrontiers
Google + Meta down to 64% of spendConcentration

12 months · Tier-2 vision

Board-credible ~30% growth plan (~$45M) on diversified, defensible channelsThe raise
CAC ≤$90 · ROAS 2.3x+ · concentration at 56% · sleepwear at 14% of revenueThe scorecard

The Ask

Four approvals. No budget increase.

Nothing in this Brief asks the board for more money. It asks for permission to stop buying the most expensive traffic in the category, and for a measurement standard honest enough to tell you whether that was right.

The Holdout as the measurement standard

Approve the geo/matched-market holdout — 24 DMAs, $340K ring-fenced, pre-registered at 90% CI — as the way brand spend gets judged. Incremental ROAS, not 7-day last-click.

The Change Platform reposition

Approve the life-stage repositioning of the lead narrative around peri/menopause relief, the binding relief-not-shame lexicon, and the reactivation of the founder-origin creative.

The reallocation, not an increase

Approve rotating $1.01M off generic Google head terms into the hormonal cluster and off-platform reach — taking Google + Meta from 70% to 56% of spend on a flat $8.4M budget.

The confidence-tiered scorecard

Accept the confidence-tiered success metrics — including that the two Low bets are measured by signed pilots and partnerships, not by 90-day revenue, and that $185K is ring-fenced for them.

What each approval unlocks: #1 makes the other three measurable. #2 is the only one that changes what the customer sees. #3 is the only one that moves money. #4 is the one that keeps a good 12-month bet from being killed by a 90-day report. They are sequenced, and #1 comes first.

Engineeredfor the change.

Flat topline, climbing CAC, illegible differentiation — and 70% of spend trapped in two channels.

Working — real, durable assets

Broken — and all three are fixable

"Scale Google 40% and grow into the number."

The 7-day ruler over-credits Google and starves everything that builds the brand.

Ranked by 7-day CPA, the library is upside down.

A large, growing category — with a cohort whose need is acute and unmet.

Everyone says cooling. Nobody can say this.

The brands actually talking to her

What the tail is doing to your claim

Narrow the message.Expand the market.

The market already named it: peri/menopause sleep relief.

This cohort was not selected. It was discovered.

68% female · median age 47

~17.5% hormonal queries

22% cite hormonal temperature

890 unprompted mentions

Win the core first. Broaden deliberately. Let the halo pull.

"The Change" — women 40–58

Thermostat-conflict couples & hot sleepers

Wellness-optimizing affluent

Nine moves.Three horizons.

Sequenced by confidence, not by hope.

Prove the brand pays — the Holdout Board Deck.

The Change Platform — own the customer the data already shows is buying.

Two fast Tier-1 proof points while the Holdout runs.

Reinstate The Two High

Night-Sweat Search Capture High

Industrialize the 6,800-review corpus into a creative factory.

Production plan

Guardrails on the format

The demand already exists. It costs a third of what you're paying now.

Stop sending hormonal queries to a generic PDP.

Thermostat Treaty — so the menopause-lead bet never reads as audience-narrowing.

Off Google, Meta,TikTok & IG.

Channels the cooling clones can't copy.

Four quarters from $112 to ≤$90 — without a dollar of new budget.

$112 CAC · 1.8x ROAS

$108 CAC · holdout live

≤$100 CAC · reposition live

≤$90 CAC · 2.3x ROAS

Every move ladders to two board outcomes.

Kill rules · act immediately

Scale rules · pour fuel

What would have to go wrong — and what we've already done about it.

Stand it up, launch, read, then scale into ~30% growth.

Four approvals. No budget increase.

The Holdout as the measurement standard

The Change Platform reposition

The reallocation, not an increase

The confidence-tiered scorecard

Let's growthe MOST.

Engineered
for the change.

Narrow the message.
Expand the market.

Nine moves.
Three horizons.

Off Google, Meta,
TikTok & IG.

Let's grow
the MOST.